Lifecore Biomedical, a fully-integrated injectables contract development and manufacturing organisation (CDMO), has signed a new agreement with a global pharmaceutical company. Under the terms of the agreement, Lifecore will perform technical transfer services to support the commercial production of an injectable suspension product for neurological disorders.
‘With this significant new customer win, we have secured our seventh agreement for a late-stage programme within the last seven months, reflecting how our focused business development efforts have created strong momentum and results for continued portfolio growth’, said Paul Josephs, chief executive officer of Lifecore. ‘Being selected to produce this higher-viscosity suspension formulation demonstrates confidence in Lifecore’s technical know-how and exceptional quality track record.
‘This opportunity also highlights the increasing demand for specialised manufacturing expertise to produce high-viscosity and other complex pharmaceutical products. Lifecore’s unique capabilities position us as a valuable partner, able to address the diverse needs of multinational pharmaceutical companies seeking to leverage manufacturing operations in the US’, said Michael Ehlers, chief executive officer of Ascidian.
